Want to join the conversation?
$LLY 3Q15 total OpEx declined by 7% or over $200MM YoverY. R&D expense declined 10%, driven by 2014 charge associated with the termination of tabalumab development and favorable FX rate impact. By geography, US pharma revenue was up 13%, driven by volume, partially offset by price.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?